New treatment for IBS and constipation

NHS patients in Wales will now have access to a first-in-class pharmaceutical treatment for irritable bowel syndrome with constipation (IBS-C). The positive recommendation by the All Wales Medicines Strategy Group (AWMSG) of Constella (linaclotide) will offer a treatment option to people in Wales who live with this chronic, relapsing disorder.  Linaclotide is an oral, once-daily guanylate cyclase-C receptor agonist (GCCA), licensed for the symptomatic treatment of moderate-to-severe irritable bowel syndrome with constipation (IBS-C) in adults. The AWMSG has recommended its use in adults whose symptoms remain uncontrolled and who have tried antispasmodics and/or laxatives. It is estimated that approximately 10.5% (255,000) of